Cargando…
HDAC6 in Diseases of Cognition and of Neurons
Central nervous system (CNS) neurodegenerative diseases are characterized by faulty intracellular transport, cognition, and aggregate regulation. Traditionally, neuroprotection exerted by histone deacetylase (HDAC) inhibitors (HDACi) has been attributed to the ability of this drug class to promote h...
Autor principal: | LoPresti, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822434/ https://www.ncbi.nlm.nih.gov/pubmed/33374719 http://dx.doi.org/10.3390/cells10010012 |
Ejemplares similares
-
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2019) -
Tau in Oligodendrocytes Takes Neurons in Sickness and in Health
por: LoPresti, Patrizia
Publicado: (2018) -
Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2022) -
Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2018) -
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
por: Simões-Pires, Claudia, et al.
Publicado: (2013)